Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.2802
-0.0197 (-6.57%)
Streaming Delayed Price
Updated: 12:12 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
April 21, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
April 21, 2022
Via
Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
April 21, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...
Via
FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
April 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
April 18, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
April 14, 2022
Via
Investor Brand Network
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
April 13, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
April 13, 2022
Via
Investor Brand Network
Why Psychedelics Could Soon Replace Antidepressants
April 13, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...
Via
FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
April 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
April 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
April 08, 2022
Via
Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
April 08, 2022
From
Cybin Inc.
Via
Business Wire
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
April 07, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
April 06, 2022
Via
Investor Brand Network
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
April 06, 2022
From
Cybin Inc.
Via
Business Wire
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
April 04, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
April 01, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
April 01, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
April 01, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development
March 31, 2022
Via
Investor Brand Network
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
March 31, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program
March 30, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program
March 29, 2022
Via
Investor Brand Network
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
March 29, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,...
Via
FinancialNewsMedia
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
March 29, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone
March 25, 2022
Via
Investor Brand Network
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.